What is the 13F Pro Quality Score for CALC?

13F Pro ranks CalciMedica, Inc. (CALC) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CALC's current score at https://13fpro.ai/research/CALC (free sign-up required for the full ranking).

Where does 13F Pro source CALC data?

All CalciMedica, Inc. fundamentals and ownership data come directly from SEC EDGAR. CalciMedica, Inc. files with the SEC under CIK 1534133. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CALC in?

CalciMedica, Inc. (CALC) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CALC research updated on 13F Pro?

CALC's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

CalciMedica, Inc.(CALC)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1534133 CALC stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

CALC Stock Analysis & AI Quality Score

AI stock analysis and institutional research for CalciMedica, Inc. (CALC), a Healthcare sector company. CALC is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), CalciMedica, Inc. reports net income of $5.0M, free cash flow of $-4.9M. Top institutional holders of CALC by reported 13-F value include JANE STREET GROUP,, VANGUARD CAPITAL MANAGEMENT, RENAISSANCE TECHNOLOGIES, based on the most recent SEC filings. CALC trades on the Nasdaq exchange and files with the SEC under CIK 1534133. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CALC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CalciMedica, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$5.0M

Free Cash Flow

Q1 2026

$-4.9M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

+60.1% YoY

$-13.7MFY 2024

FY21 $-35.8MFY22 $-7.8MFY23 $-34.4MFY24 $-13.7M

Operating Income

+36.4% YoY

$-24.2MFY 2024

FY21 $-35.9MFY22 $-14.2MFY23 $-38.1MFY24 $-24.2M

EPS (Diluted)

+68.1% YoY

$-1.22FY 2024

FY21 $-0.84FY22 $-55.58FY23 $-3.83FY24 $-1.22

Total Assets

+62.4% YoY

$19.8MFY 2024

FY21 $69.1MFY22 $3.3MFY23 $12.2MFY24 $19.8M

Op. Cash Flow

+17.8% YoY

$-21.1MFY 2024

FY21 $-31.5MFY22 $-11.8MFY23 $-25.7MFY24 $-21.1M

Metric	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2018
Net Income	$-13.7M +60.1%	$-34.4M -339.1%	$-7.8M +78.2%	$-35.8M -30.1%	$-27.5M	—
Operating Income	$-24.2M +36.4%	$-38.1M -168.3%	$-14.2M +60.5%	$-35.9M -20.5%	$-29.8M	—
EPS (Diluted)	$-1.22 +68.1%	$-3.83 +93.1%	$-55.58 -6477.5%	$-0.84	—	—
Total Assets	$19.8M +62.4%	$12.2M +263.8%	$3.3M -95.2%	$69.1M -32.1%	$101.8M	—
Operating Cash Flow	$-21.1M +17.8%	$-25.7M -118.8%	$-11.8M +62.7%	$-31.5M +1.8%	$-32.1M	—

AI Insight: CALC Financial Trends

CalciMedica swung to net profitability in Q1 2026 ($5M) after eight consecutive quarters of losses, though operating income remained negative.

• Net income turned positive $5M in Q1 2026 versus $-11M in Q4 2025, a $16M sequential improvement.

• Operating cash flow stabilized near $-5M across most recent four quarters; no material deterioration.

• Equity eroded from $14M (Q2 2024) to $-1M (Q1 2026), signaling cumulative cash burn consumed shareholder value.

⚠ Operating income remains deeply negative ($-6M in Q1 2026) despite net profit swing—suggests one-time gain masked underlying losses.

⚠ No revenue data reported across all eight quarters; inability to assess top-line trajectory or unit economics.

⚠ Negative equity of $-1M in Q1 2026 indicates technical insolvency; balance sheet severely constrained.

AI Insight: CALC Ratio Trends

CalciMedica data insufficient to identify trends; only three quarters show ROE/ROA metrics, all deeply negative.

• ROE and ROA both deteriorated sharply: ROE fell from -114.3% (Q2 2024) to -185.2% (Q1 2025); ROA worsened from -75.1% to -79.6%.

• Vast majority of key metrics (OpMargin, NPM, ROIC, D/E) are missing across all periods; cannot assess profitability or leverage trends.

⚠ ROE deteriorated 71pp in one quarter (Q4 2024 to Q1 2025), signaling acute earnings or equity volatility. Monitor next disclosed quarter.

⚠ No data beyond Q1 2025; cannot confirm whether losses have stabilized, improved, or worsened in latter 2025 or Q1 2026.

Get alerted when CALC's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for CalciMedica, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CALC

JANE STREET GROUP, LLC
$96.4K178,515 sh
VANGUARD CAPITAL MANAGEMENT LLC
$91.3K169,110 sh
RENAISSANCE TECHNOLOGIES LLC
$69.2K128,075 sh
180 WEALTH ADVISORS, LLC
$68.3K126,500 sh
GEODE CAPITAL MANAGEMENT, LLC
$66.7K123,382 sh
Stonehage Fleming Financial Services Holdings Ltd
$29.0K53,703 sh
VANGUARD FIDUCIARY TRUST CO
$24.7K45,829 sh
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$16.6K30,716 sh
CITADEL ADVISORS LLC
$9.8K18,200 sh
STATE STREET CORP
$9.2K17,073 sh

Fund	Value	Shares
JANE STREET GROUP, LLC	$96.4K	178,515
VANGUARD CAPITAL MANAGEMENT LLC	$91.3K	169,110
RENAISSANCE TECHNOLOGIES LLC	$69.2K	128,075
180 WEALTH ADVISORS, LLC	$68.3K	126,500
GEODE CAPITAL MANAGEMENT, LLC	$66.7K	123,382
Stonehage Fleming Financial Services Holdings Ltd	$29.0K	53,703
VANGUARD FIDUCIARY TRUST CO	$24.7K	45,829
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$16.6K	30,716
CITADEL ADVISORS LLC	$9.8K	18,200
STATE STREET CORP	$9.2K	17,073

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CALC on your watchlist

Track score changes the day CalciMedica, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CALC a good stock to buy?

13F Pro's AI-powered analysis of CalciMedica, Inc. (CALC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CALC are available on the CALC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own CALC?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CALC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of CalciMedica, Inc.'s investment landscape.